Kwok-Leung Ong1, Robyn L McClelland2, Matthew A Allison3, John Kokkinos4, Ben J Wu4, Philip J Barter4, Kerry-Anne Rye4. 1. Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: oklws@yahoo.com.hk. 2. Department of Biostatistics, University of Washington, Seattle, WA, United States. 3. Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, United States. 4. Lipid Research Group, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
Abstract
BACKGROUND AND AIMS: Fibroblast growth factor 21 (FGF21) plays an important role in glucose and lipid metabolism. We have investigated the relationship of plasma FGF21 levels with both prevalent and incident metabolic syndrome (MetS) in participants from the Multi-Ethnic Study of Atherosclerosis (MESA). METHODS: 5783 participants from four major ethnic groups (non-Hispanic white, African American, Hispanic American, and Chinese American) were included in the cross-sectional analysis. Longitudinal analysis involved 3479 participants without MetS at baseline, of whom 1100 participants developed incident MetS over 9.2 years. RESULTS: Elevated FGF21 levels were found in participants with prevalent MetS (median [interquartile range] = 189.4 [114.4-302.1] vs. 123.7 [65.9-210.3] pg/mL, p < 0.001) or incident MetS (145.6 [84.9-240.8] vs 112.0 [57.0-194.5] pg/mL, p < 0.001), compared to those without. After adjusting for baseline demographic, socioeconomic and lifestyle factors, as well as cardiovascular risk factors and biomarkers, and compared to the lowest quartile, the highest FGF21 quartile was associated with prevalent MetS (odds ratio 2.80; 95% confidence interval, 2.30-3.40, p < 0.001). Among participants without MetS at baseline, the highest FGF21 quartile was associated with higher risk of incident MetS (hazards ratio 1.76; 95% confidence interval, 1.46-2.12, p < 0.001). Similar results were obtained when assessing ln-transformed FGF21 levels. Overall, no significant interaction was found with age, sex, and race/ethnicity for both prevalent and incident MetS. CONCLUSIONS: Higher FGF21 levels significantly predict the development of MetS in an ethnically diverse population followed long term. Further studies are needed to confirm the potential role of FGF21 as a biomarker for MetS.
BACKGROUND AND AIMS: Fibroblast growth factor 21 (FGF21) plays an important role in glucose and lipid metabolism. We have investigated the relationship of plasma FGF21 levels with both prevalent and incident metabolic syndrome (MetS) in participants from the Multi-Ethnic Study of Atherosclerosis (MESA). METHODS: 5783 participants from four major ethnic groups (non-Hispanic white, African American, Hispanic American, and Chinese American) were included in the cross-sectional analysis. Longitudinal analysis involved 3479 participants without MetS at baseline, of whom 1100 participants developed incident MetS over 9.2 years. RESULTS: Elevated FGF21 levels were found in participants with prevalent MetS (median [interquartile range] = 189.4 [114.4-302.1] vs. 123.7 [65.9-210.3] pg/mL, p < 0.001) or incident MetS (145.6 [84.9-240.8] vs 112.0 [57.0-194.5] pg/mL, p < 0.001), compared to those without. After adjusting for baseline demographic, socioeconomic and lifestyle factors, as well as cardiovascular risk factors and biomarkers, and compared to the lowest quartile, the highest FGF21 quartile was associated with prevalent MetS (odds ratio 2.80; 95% confidence interval, 2.30-3.40, p < 0.001). Among participants without MetS at baseline, the highest FGF21 quartile was associated with higher risk of incident MetS (hazards ratio 1.76; 95% confidence interval, 1.46-2.12, p < 0.001). Similar results were obtained when assessing ln-transformed FGF21 levels. Overall, no significant interaction was found with age, sex, and race/ethnicity for both prevalent and incident MetS. CONCLUSIONS: Higher FGF21 levels significantly predict the development of MetS in an ethnically diverse population followed long term. Further studies are needed to confirm the potential role of FGF21 as a biomarker for MetS.
Authors: Christian Schlein; Saswata Talukdar; Markus Heine; Alexander W Fischer; Lucia M Krott; Stefan K Nilsson; Martin B Brenner; Joerg Heeren; Ludger Scheja Journal: Cell Metab Date: 2016-02-04 Impact factor: 27.287
Authors: Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima Journal: Circ Heart Fail Date: 2012-10-02 Impact factor: 8.790
Authors: Saswata Talukdar; Yingjiang Zhou; Dongmei Li; Michelle Rossulek; Jennifer Dong; Veena Somayaji; Yan Weng; Ronald Clark; Adhiraj Lanba; Bryn M Owen; Martin B Brenner; Jeffrey K Trimmer; Kathryn E Gropp; Jeffrey R Chabot; Derek M Erion; Timothy P Rolph; Bryan Goodwin; Roberto A Calle Journal: Cell Metab Date: 2016-03-08 Impact factor: 27.287
Authors: Takeshi Inagaki; Paul Dutchak; Guixiang Zhao; Xunshan Ding; Laurent Gautron; Vinay Parameswara; Yong Li; Regina Goetz; Moosa Mohammadi; Victoria Esser; Joel K Elmquist; Robert D Gerard; Shawn C Burgess; Robert E Hammer; David J Mangelsdorf; Steven A Kliewer Journal: Cell Metab Date: 2007-06 Impact factor: 27.287
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Cheng Chen; Bernard M Y Cheung; Annette W K Tso; Yudong Wang; Lawrence S C Law; Kwok Leung Ong; Nelson M S Wat; Aimin Xu; Karen S L Lam Journal: Diabetes Care Date: 2011-07-12 Impact factor: 19.112
Authors: Yu Cho Woo; Chi Ho Lee; Carol H Y Fong; Aimin Xu; Annette W K Tso; Bernard M Y Cheung; Karen S L Lam Journal: Clin Endocrinol (Oxf) Date: 2016-09-29 Impact factor: 3.478
Authors: Brittany L Mason; Abu Minhajuddin; Andrew H Czysz; Manish K Jha; Bharathi S Gadad; Taryn L Mayes; Madhukar H Trivedi Journal: Transl Psychiatry Date: 2022-01-11 Impact factor: 6.222